Last reviewed · How we verify
(alprax) alprazolam
Alprazolam enhances the inhibitory effects of GABA at the GABA-A receptor in the central nervous system, reducing neuronal excitability and producing anxiolytic and sedative effects.
Alprazolam enhances the inhibitory effects of GABA at the GABA-A receptor, reducing neuronal excitability and producing anxiolytic and sedative effects. Used for Anxiety disorder, Panic disorder, Generalized anxiety disorder.
At a glance
| Generic name | (alprax) alprazolam |
|---|---|
| Sponsor | B.P. Koirala Institute of Health Sciences |
| Drug class | Benzodiazepine |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | FDA-approved |
Mechanism of action
Alprazolam is a benzodiazepine that binds to GABA-A receptors, which are ligand-gated chloride channels. By potentiating GABA's action, it increases chloride ion influx into neurons, hyperpolarizing the cell membrane and reducing the likelihood of action potential firing. This results in decreased anxiety, muscle relaxation, and sedation.
Approved indications
- Anxiety disorders
- Panic disorder
- Generalized anxiety disorder
Common side effects
- Drowsiness
- Dizziness
- Fatigue
- Cognitive impairment
- Dependence/withdrawal risk
- Ataxia
Key clinical trials
- Premedication With Melatonin and Alprazolam Combination Versus Alprazolam or Melatonin Alone (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- (alprax) alprazolam CI brief — competitive landscape report
- (alprax) alprazolam updates RSS · CI watch RSS
- B.P. Koirala Institute of Health Sciences portfolio CI